|
February 19, 2026
Treatment for Brain Metastases With Stereotactic Radiation
vs Hippocampal-Avoidance Whole Brain Radiation
A RandomizedClinical Trial
AyalA.Aizer,MD,MHS;Kee-YoungShin,MS;PaulJ.Catalano,ScD;IvyRicca,BA;MarcianaJohnson,MPH;
GrantBenham;KristinRoper,PhD;BeverlySpicer,RN;EileenMann,RN;JenniferNosker,PhD;
MichaelW.Parsons,PhD;MallikaL.Mendu,MD,MBA;JaroslawHepel,MD;FallonChipidza,MD;
MonicaKrishnan,MD;DianaD.Shi,MD;NayanLamba,MD;ItaiPashtan,MD;LukePeng,MD;
BrianAlexander,MD,MPH;PaulD.Brown,MD;PatrickY.Wen,MD;DaphneA.Haas-Kogan,MD;
RifaquatRahman,MD;ShyamTanguturi,MD
This recent clinical trial compared two radiation approaches for people with 5-20 brain metastases who had not been previously treated with brain radiation: targeted stereotactic radiation, which treats only the tumors, and whole brain radiation with hippocampal avoidance. Over six months, patients who received the targeted approach reported fewer symptoms and less disruption to their daily life. While both treatments reported similar amount of serious side effects, fatigue was more common with whole brain radiation. These findings suggest that focusing radiation directly on the tumors may better support patients quality of life.
| 
